Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Since 2020, COVID-19 has surged across the nation and the world. With variants like Omicron, Delta, Alpha and more, this ...

Concerns about COVID-19 have significantly diminished, but researchers continue to analyze its high transmission rate, aiming ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

KP.3 was the 'predominant' SARS-CoV-2 variant in the US. It was also spreading in Europe. It's now joined with another ...

The company is focusing on respiratory vaccines, including RSV, Flu, and COVID-19 variants, to sustain and grow its revenue streams. Despite massive R&D expenditures and significant losses ...

Opens in a new tab or window Since early in the COVID-19 pandemic, epidemiologic studies demonstrated ... particularly in the ...

LTV is more effective than NTV and ETV against Mpro mutants, making it a promising candidate for treating drug-resistant ...

From 11.7 percent to 23.4 percent of adults infected with the novel coronavirus experienced ... the virus during the outbreak of the Alpha and Delta variants in spring and summer 2021, 25 ...

Alpha-1 antitrypsin deficiency (AATD ... immune cell resident in the lungs. Study reveals that COVID-19 significantly increases the risk of chronic fatigue syndrome, with specific populations ...